Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Clinical use of beta-blockers in patients with heart failure
Autore:
Eichhorn, EJ;
Indirizzi:
Univ Texas, SW Med Ctr, Dept Vet Affairs Hosp, Dallas, TX 75216 USA Univ Texas Dallas TX USA 75216 ept Vet Affairs Hosp, Dallas, TX 75216 USA
Titolo Testata:
JOURNAL OF CARDIAC FAILURE
fascicolo: 2, volume: 6, anno: 2000, supplemento:, 1
pagine: 40 - 46
SICI:
1071-9164(200006)6:2<40:CUOBIP>2.0.ZU;2-P
Fonte:
ISI
Lingua:
ENG
Soggetto:
IDIOPATHIC DILATED CARDIOMYOPATHY; LEFT-VENTRICULAR FUNCTION; ADRENERGIC-BLOCKADE; DOUBLE-BLIND; VASODILATOR THERAPY; MYOCARDIAL-FUNCTION; BLOCKING-AGENTS; CARVEDILOL; PLACEBO; METOPROLOL;
Keywords:
heart failure; beta-adrenergic receptor blocking agents; myocardial function;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
30
Recensione:
Indirizzi per estratti:
Indirizzo: Eichhorn, EJ Univ Texas, SW Med Ctr, Dept Vet Affairs Hosp, 5323 Harry Hines Blvd, Dallas, TX 75216 USA Univ Texas 5323 Harry Hines Blvd Dallas TX USA 75216 5216 USA
Citazione:
E.J. Eichhorn, "Clinical use of beta-blockers in patients with heart failure", J CARD FAIL, 6(2), 2000, pp. 40-46

Abstract

Recognition of the role of the sympathetic nervous system in chronic heartfailure has resulted in dramatic changes in the way heart failure is viewed, providing strong evidence for the therapeutic role for beta-adrenergic blocking agents. This treatment strategy does not provide short-term hemodynamic improvement and may even worsen symptoms initially. However, beta-blockers can be administered with good or even excellent tolerability by slowlywithdrawing adrenergic support to the failing heart. Results of clinical trials have shown that long-term treatment with beta-blockers improves ventricular function and reduces mortality rates in patients with mild-to-moderate heart failure. Although the improvement in ventricular function is a beta-blocker class effect, there are distinct differences in antiadrenergic activity and tolerability among the first-, second-, and third-generation agents. These differences-as well as practical strategies for dose titration and the management of decompensation-are the focus of this article.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 07/04/20 alle ore 21:35:20